A randomized, double-blind, placebo-controlled clinical trial was designed to treat active lupus patients who received IL-2 at a dose of 1 million IU or placebo with standard treatment for 3 months and were followed for another 3 months. This evidence concerns the gene IL2 and systemic lupus erythematosus.